Peritoneal dialysis in acute renal failure

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorGabriel, Daniela Ponce
dc.creatorNascimento, Ginivaldo Victor R.
dc.creatorCaramori, Jacqueline Socorro Costa Teixeira
dc.creatorMartim, Luís Cuadrado
dc.creatorBarretti, Pasqual
dc.creatorBalbi, André Luis
dc.date2014-05-27T11:21:57Z
dc.date2016-10-25T18:22:36Z
dc.date2014-05-27T11:21:57Z
dc.date2016-10-25T18:22:36Z
dc.date2006-09-01
dc.date.accessioned2017-04-06T01:20:09Z
dc.date.available2017-04-06T01:20:09Z
dc.identifierRenal Failure, v. 28, n. 6, p. 451-456, 2006.
dc.identifier0886-022X
dc.identifier1525-6049
dc.identifierhttp://hdl.handle.net/11449/69057
dc.identifierhttp://acervodigital.unesp.br/handle/11449/69057
dc.identifier10.1080/08860220600781245
dc.identifierWOS:000239966600001
dc.identifier2-s2.0-33747793706
dc.identifierhttp://dx.doi.org/10.1080/08860220600781245
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/890351
dc.descriptionThe definition of adequate dialysis in acute renal failure (ARF) is complex and involves the time of referral to dialysis, dose, and dialytic method. Nephrologist experience with a specific procedure and the availability of different dialysis modalities play an important role in these choices. There is no consensus in literature on the best method or ideal dialysis dose in ARF. Peritoneal dialysis (PD) is used less and less in ARF patients, and is being replaced by continuous venovenous therapies. However, it should not be discarded as a worthless therapeutic option for ARF patients. PD offers several advantages over hemodialysis, such as its technical simplicity, excellent cardiovascular tolerance, absence of an extracorporeal circuit, lack of bleeding risk, and low risk of hydro-electrolyte imbalance. PD also has some limitations, though: it needs an intact peritoneal cavity, carries risks of peritoneal infection and protein losses, and has an overall lower effectiveness. Because daily solute clearance is lower with PD than with daily HD, there have been concerns that PD cannot control uremia in ARF patients. Controversies exist concerning its use in patients with severe hypercatabolism; in these cases, daily hemodialysis or continuous venovenous therapy have been preferred. There is little literature on PD in ARF patients, and what exists does not address fundamental parameters such as adequate quantification of dialysis and patient catabolism. Given these limitations, there is a pressing need to re-evaluate the adequacy of PD in ARF using accepted standards. Therefore, new studies should be undertaken to resolve these problems. Copyright © Informa Healthcare.
dc.languageeng
dc.relationRenal Failure
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAcute renal failure
dc.subjectAdequacy
dc.subjectPeritoneal dialysis
dc.subjectacute kidney failure
dc.subjectbleeding
dc.subjectelectrolyte disturbance
dc.subjectextracorporeal circulation
dc.subjecthemodialysis
dc.subjecthuman
dc.subjecthyperglycemia
dc.subjectperitoneal dialysis
dc.subjectperitonitis
dc.subjectpriority journal
dc.subjectprotein depletion
dc.subjectreview
dc.subjecturemia
dc.subjectAcute Kidney Injury
dc.subjectHumans
dc.subjectKidney Failure, Acute
dc.subjectPeritoneal Dialysis
dc.subjectTreatment Outcome
dc.titlePeritoneal dialysis in acute renal failure
dc.typeOtro


Este ítem pertenece a la siguiente institución